Keyword: Merck & Co.

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.

Only weeks ago, Merck's I-O superstar Keytruda whiffed in a key lung cancer trial. Now the therapy is facing pushback from England's cost watchdog.

In a heated race against GSK in the PARP inhibitor market, AstraZeneca and Merck nabbed a helpful FDA boost for its Lynparza in ovarian cancer.

Merck, Eli Lilly and Amgen will face the HHS in appeals court Monday, looking to extend their trial court win against drug prices in TV ads.

Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.

Approvals in metastatic bladder cancer in hand, Keytruda has become the first PD-1/L1 to win an FDA nod in non-muscle invasive bladder cancer.